肝细胞癌中的新辅助免疫检查点抑制剂:元分析和系统性审查
Chunhong Tian1, Yifan Yu1, Yuqing Wang1
1The First Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou, China.
Frontiers in immunology
|March 5, 2024
概括
新辅助免疫疗法对可切除肝细胞癌 (HCC) 有望,具有显著的病理反应率. 需要进一步的高质量研究来确认不同治疗方案的疗效和安全性.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 肝细胞癌研究 肝细胞癌研究
背景情况:
- 缺乏用于肝细胞癌 (HCC) 的新辅助免疫治疗的标准化方案.
- 新辅助免疫疗法在其他癌症类型中也显示出好处.
- 研究新辅助免疫疗法在可切除的HCC中的作用至关重要.
研究的目的:
- 系统地审查和元分析新辅助免疫疗法在可切除的HCC中的疗效.
- 评估HCC患者新辅助免疫治疗的安全性.
- 为了比较不同的新辅助免疫疗法策略.
主要方法:
- 主要数据库和会议记录的系统搜索.
- 包括用新辅助免疫疗法治疗可切除的HCC的临床试验.
- 单臂元分析以计算反应率和不良事件发生率.
主要成果:
- 新辅助免疫疗法产生了47%的重大病理反应率和22%的病理完整反应率.
- 客观反应率为37%,与治疗相关的3-4级不良事件发生率为35%.
- 双重免疫检查点抑制剂 (ICI) 与其他组合相比,显示出更高的疗效但更低的安全性.
结论:
- 新辅助免疫疗法是可切除HCC的有益治疗方法.
- 双重ICI联合治疗显示出更高的疗效,但毒性增加.
- 需要高质量的大规模研究才能得出最终的结论.
更多相关视频
相关概念视频
01:27Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K